Analyst
Cantor
Equibles does not estimate personal net worth.
Josh Shimmer is recorded as Analyst at Cantor. Josh Shimmer has spoken on 3 earnings calls and 2 other investor events across 5 companies, most recently for Neurocrine Biosciences Inc on July 30, 2026. Those appearances were for Neurocrine Biosciences Inc (NBIX), Mirum Pharmaceuticals, Inc. (MIRM), Invivyd, Inc. (IVVD), DiaMedica Therapeutics Inc. (DMAC) and Rocket Pharmaceuticals, Inc. (RCKT). The companies whose calls Josh Shimmer spoke on are classified in the Healthcare sector.
“How are you thinking about the ability to smooth top and bottom line growth through the 2029 Ingressa IRA implementation year? And does the answer to that question depend on your phase three readouts next year?”
“Also on Zalurgis, Sertib, how are you thinking about its differentiation versus maybe some of the other programs in development? Gretas, so Gretas, Matt, if I'm pronouncing that right, and Soho Knows, that's number one.”
“First, how long do you expect it will take to enroll the incremental 500 subjects? The press release suggests some uncertainty around that, but maybe you can give a bit of a range.”
“For the evaluation of DM199 in earlier onset preeclampsia, how do you think about the potential risk of the protein crossing the placental barrier at that stage?”
Cantor
Analyst
Transcript header (unverified)
Drug Manufacturers - Specialty & Generic · Healthcare
IVVD
Biotechnology · Healthcare
